| Literature DB >> 31030827 |
James D Holt1, Fereshteh Gerayli2.
Abstract
Whether to screen for prostate cancer in aging men is a topic that is fairly well researched, but recommendations are controversial, because the evidence supporting any recommendation is equivocal. The evidence clearly does not support routine screening of all average-risk men, but for men aged 55 to 69 years, either not routinely screening, or engaging each man in shared decision making for his individual preference on screening, is reasonable and consistent with the evidence. Many organizations, including the American Cancer Society, have not yet reassessed their guidelines, in response to the US Preventative Services Task Force revised guideline.Entities:
Keywords: Overdiagnosis; PSA; PSA screening; Prostate cancer; Prostate cancer screening; Prostate cancer treatment
Mesh:
Substances:
Year: 2019 PMID: 31030827 DOI: 10.1016/j.pop.2019.02.007
Source DB: PubMed Journal: Prim Care ISSN: 0095-4543 Impact factor: 2.907